King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
14:30
Neymar sent off after a huge scandal in Santos - Bahia 1-1
14:15
Pavel Popescu accuses Ilie Bolojan of blocking Romania’s candidacy for the ITU Council, following the dispute over protocol expenses
13:59
Oana Gheorghiu accuses the PSD of double standards regarding the deficit and claims that the Social Democrats compare different indicators to criticize the Bolojan government
13:43
The U.S. Embassy salutes the Romanian Armed Forces and announces military cooperation to defend NATO’s eastern flank
13:23
A British pensioner sold his Pokémon collection, forgotten in an attic for 15 years, for £1.56 million
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
